Interaction of antitumor agents including carboquone in sarcoma-180 system.
Combination effect of antitumor agents including carboquone was evaluated on the concept of pharmacological synergism and not therapeutic synergism in ascites sarcoma-180 system. Combinations of carboquone plus cyclophosphamide, doxorubicin, and Methotrexate in simultaneous administration and carboquone plus doxorubicin in alternate one provided synergism. Combination effect of agents was affected by the schedule of drug administration. Toxicity of carboquone in combination with many antitumor agents, generally, decreased in simultaneous administration. Approved agents in combination with carboquone in simultaneous administration were Mitomycin-C, daunorubicin, Actinomycin-d, vinblastine, vincristine, Ancytabine, and 6-mercaptopurine. Those in alternate administration were Actinomycin-D and vinblastine.
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001389:Azirines / Q000627:therapeutic use*; D002225:Carbazilquinone / Q000009:adverse effects / Q000627:therapeutic use*; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005260:Female; D051379:Mice; D012510:Sarcoma 180 / Q000188:drug therapy*
D000970:Antineoplastic Agents; D001389:Azirines; D002225:Carbazilquinone